AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in 3 large clinical trials covering 5 out of 6 genotypes of the virus, and it is likely to receive marketing approval in the United States and European Union as the first ribavirin-free pangenotypic direct-acting antiviral combination next year, according to a report at the AASLD Liver Meeting last week in Boston.
